FOCINVEZ™ Administration Recommendations
The first and only ready-to-use presentation of fosaprepitant — without the need for dilution or reconstitution1,2
FOCINVEZ™ is supplied in the dose strength of 150 mg/50 mL (3 mg/mL).1 Please see Full Prescribing Information for a complete list of indications and dosing schedule.
References: 1. FOCINVEZ. Prescribing information. Amneal Pharmaceuticals LLC; 2026. 2. U.S. Food and Drug Administration. Orange book: Approved drug products with therapeutic equivalence evaluations. Accessed September 15, 2026. https://www.accessdata.fda.gov/scripts/cder/ob/search_product.cfm
FOCINVEZ™ is a substance P/neurokinin-1(NK1) receptor antagonist, indicated in adults and pediatric patients 6 months of age and older, in combination with other antiemetic agents, for the prevention of:
Limitations of Use:
FOCINVEZ™ has not been studied for treatment of established nausea and vomiting.
Clinically Significant CYP3A4 Drug Interactions: Fosaprepitant, a prodrug of aprepitant, is a weak inhibitor of CYP3A4, and aprepitant is a substrate, inhibitor, and inducer of CYP3A4.
Hypersensitivity Reactions: Serious hypersensitivity reactions, including anaphylaxis and anaphylactic shock, during or soon after infusion of fosaprepitant have occurred. Symptoms including flushing, erythema, dyspnea, hypotension and syncope have been reported. Patients should be monitored during and after infusion. If hypersensitivity reactions occur, discontinue the infusion and administer appropriate medical therapy. Do not reinitiate FOCINVEZ™ in patients who experience these symptoms with previous use.
Infusion Site Reactions: Infusion site reactions (ISRs) have been reported with the use of intravenous fosaprepitant. The majority of severe ISRs, including thrombophlebitis and vasculitis, were reported with concomitant vesicant (anthracycline-based) chemotherapy administration, particularly when associated with extravasation. Necrosis was also reported in some patients with concomitant vesicant chemotherapy. Most ISRs occurred with the first, second or third exposure to single doses of intravenous fosaprepitant and in some cases, reactions persisted for two weeks or longer. Treatment of severe ISRs consisted of medical, and in some cases surgical, intervention. Avoid infusion of FOCINVEZ™ into small veins or through a butterfly catheter. If a severe ISR develops during infusion, discontinue the infusion and administer appropriate medical treatment.
Decrease INR with Concomitant Warfarin: Co-administration of fosaprepitant with warfarin, a CYP2C9 substrate, may result in a clinically significant decrease in the International Normalized Ratio (INR) of prothrombin time. Monitor the INR in patients on chronic warfarin therapy in the 2-week period, particularly at 7 to 10 days, following initiation of FOCINVEZ™ with each chemotherapy cycle.
Risk of Reduced Efficacy of Hormonal Contraceptives: The efficacy of hormonal contraceptives may be reduced during administration of and for 28 days following the last dose of fosaprepitant. Advise patients to use effective alternative or back-up methods of contraception during treatment with FOCINVEZ™ and for 1 month following administration of the last dose of fosaprepitant or oral aprepitant.
Side effects other than those listed above are possible with the use of FOCINVEZ™.
See the full Prescribing Information for a list of all possible side effects.
To report SUSPECTED ADVERSE REACTIONS, contact Amneal Global Patient Safety at 1-877-835-5472, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please read the full Prescribing Information.
PP-FOC-US-0003 10/2026
FOCINVEZ™ is a substance P/neurokinin-1(NK1) receptor antagonist, indicated in adults and pediatric patients 6 months of age and older, in combination with other antiemetic agents, for the prevention of:
+